Press Releases


ALLEGRO OPHTHALMICS AND SENJU PHARMACEUTICAL ANNOUNCE COLLABORATION IN JAPAN TO DEVELOP INTEGRIN PEPTIDE THERAPY AS FIRST IN-CLASS TREATMENT OF VASCULAR EYE DISEASES

May 02, 2013

ALLEGRO OPHTHALMICS ANNOUNCES COMPLETED ENROLLMENT OF WET AGE-RELATED MACULAR DEGENERATION STUDY WITH RESULTS TO BE PRESENTED AT ARVO; COMMENCEMENT OF PHASE IB/IIA COMBINATION THERAPY STUDY IN PATIENTS WITH DIABETIC MACULAR EDEMA

March 04, 2013

Allegro Ophthalmics Announces Presentation Of New Data At Macula 2012 On Novel Class Of Vascular Eye Disease Therapy

January 20, 2012

Allegro Ophthalmics Announces The Commencement Of Its Second Human Subject Study Using Integrin Peptide Therapy To Treat Neovascular Eye Disease

December 21, 2011

Integrin Peptide Therapy Named One Of “Top Ten Projects To Watch” At 2011 Therapeutic (TA) Partnership Meeting

December 01, 2011

Allegro Ophthalmics Presents New Class Of Treatment For Neovascular Eye Diseases At The 13th Annual Southern California Biomedical Council Investor And Partnership Conference

November 09, 2011

The Wilmer Eye Institute At Johns Hopkins Receives Helmsley Charitable Trust Research Grant For Integrin Peptide Therapy – A New Drug Class To Treat Vascular Eye Diseases

November 03, 2011

Allegro Ophthalmics Announces Completion Of Phase 1 Study, AAO Presentation

November 03, 2011

2011 Allegro Ophthalmics LLC In San Juan Capistrano Wins OCTANe’s LaunchPad Award

May 24, 2011

Dr. Hugo Quiroz-Mercado To Present Allegro Ophthalmics, LLC’s Phase 1 Human Safety Study Data At The 2011 Retina Society Annual Scientific Meeting In Rome

May 16, 2011

Share

About Allegro

Loss of vision from retinal vascular disease is a real risk for millions of people suffering from macular degeneration and ...